NCT01351896View on ClinicalTrials.gov

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 2, 2011

Primary Completion Date

July 8, 2024

Study Completion Date

May 6, 2026

Conditions
Ann Arbor Stage I Small Lymphocytic LymphomaAnn Arbor Stage II Small Lymphocytic LymphomaChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region GeneSmall Lymphocytic LymphomaSmall Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region GeneStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Pneumococcal Polyvalent Vaccine

Given IM (concurrently or sequentially)

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH